A reference class, not a person — and not every older adult. The profile: around 70, with sarcopenic obesity (excess fat and depleted muscle together), usually hypertensive, prediabetic/diabetic, MASLD-leaning, with reduced bone density, some anabolic resistance (ageing muscle responds less to protein and training), and increasing polypharmacy. This is the functionally-drifting older adult, not the frail or institutionalised — a separate stratum. It is the sibling of Big Rocks (Median), and the point of the pair is that several big rocks invert with age.
Two shifts reorder everything
- The priority outcomes change. At 70, function, muscle, bone, falls and independence are patient-important endpoints in their own right, and competing risk shortens the runway for slow-acting longevity plays. Rank on staying capable, not on mortality alone.
- The headline lever inverts. For the younger drifting adult the #1 lever is lose visceral fat. Here, aggressive energy restriction is a hazard — it accelerates the sarcopenia and bone loss this stratum can least afford. Weight loss becomes conditional and muscle-protective only.
Caveat throughout: most of the “inverts into a harm” reasoning is mechanism plus held age-moderation, not elderly-specific measured harm. Read it as conditionality, not evidenced harm.
(a) Robust, function-first — these move to the top
1. Resistance training with adequate protein — the #1 lever here.
- Its case for this group is the strong one: it builds and preserves muscle, strength and function, and (with activity) reduces falls, injurious falls and probably fractures — patient-important outcomes, the strongest outcome class the evidence carries here (Muscle-Strengthening Activity and Mortality, Physical Activity Dose and Mortality).
- Held protein target: ~1.6 g/kg/day (where added protein stops improving training-induced lean mass in healthy adults; wide CI ~1.0-2.2). Training is the driver, protein the adjunct (Protein and Resistance Training for Muscle and Strength).
- Two age caveats the evidence does carry: the protein supplement’s lean-mass benefit is reduced with age, and adequate protein plus training is how you keep muscle during any weight loss — so protein is the guardrail on the weight lever below.
- What we do NOT hold is a validated elderly-specific target — whether the anabolic-resistant older adult needs more than 1.6 g/kg, and the per-meal dose, is the top gap below, not a number to invent. (RT’s own mortality signal is very-low certainty — not why it tops the list; function is.)
2. Aerobic activity — for falls, function and mortality. The falls/fracture benefit above is held specifically for older adults; add the general mortality benefit (Physical Activity Dose and Mortality). Frailty itself is not targetable — the evidence base treats it as too ill-defined to aim at.
(b) Conditional or inverted — the younger levers that flip here
Weight / visceral fat — inverted.
- Do not prescribe aggressive energy restriction: it strips muscle and bone. If weight loss is pursued (for MASLD, glycaemia, blood pressure, mobility), it must be muscle-and-bone-protective — paired with resistance training and ~1.6 g/kg protein — and gradual.
- On rate: NICE deleted its old specific-deficit number as arbitrary and made its aggressive low-energy-replacement recommendation deliberately weak, citing rapid regain / weight cycling (Diets for Weight Loss - What NICE Recommends). So “gradual, not rapid” is guidance-weak plus mechanism (faster loss sheds more lean and bone) — not a measured rate threshold; a rate/maintenance trial is a routed gap shared with the median cut (Challenge #20).
- The honest bounds: lifestyle weight loss did not cut cardiovascular events (Look AHEAD null; a 54-RCT meta-analysis confirms), though it lowers all-cause mortality by a non-cardiovascular route (Does Weight Loss Reduce Cardiovascular Events); ≥5% clears liver fat, 7-10% reverses steatohepatitis (Fatty Liver MASLD and Weight Loss) — but here the sarcopenia/bone cost can outweigh those, so the target is body composition, not the scale.
Blood pressure, glycaemia and lipids — age-adjusted and competing-risk-aware.
- Higher absolute cardiovascular risk means BP-lowering buys real absolute benefit (Blood Pressure Lowering and Cardiovascular Events) — intensive control cut events in older high-risk adults in SPRINT, though with more hypotension, syncope and acute kidney injury (Baseline Risk and the Relative-Absolute Split).
- On lipids: LDL/apoB causally drives atherosclerosis and the dose is cumulative (LDL ApoB and Cumulative Exposure) — but competing risk and a short runway blunt the lifetime payoff, which is why guidelines pull back with age (ESC drops lipid-lowering to Class IIb at ≥70; USPSTF finds statin initiation insufficient at ≥76 — Statins for Primary Prevention and the Power of Zero CAC, SCORE2 Baseline Risk and the ESC Treatment Thresholds, Lifetime Benefit - The Frame for Younger Adults).
- Polypharmacy plus fall and orthostatic risk make over-treatment its own harm — so appraise, don’t prescribe binds harder here than anywhere.
(c) Small / contested — further demoted below function
- Saturated fat → unsaturated, free sugars, red/processed meat are small levers here, below the muscle/function priority (Saturated Fat Intake and Replacement, Free Sugars Intake, Should Adults Reduce Red and Processed Meat). One twist: meat is a protein source, which matters more here.
- Sodium — with the emphasis reversed: a small BP lever, but over-restriction (of sodium or energy) can worsen appetite, intake and frailty in the old — so the aggressive-cut framing of the younger guide is itself a hazard here (Sodium Intake and Blood Pressure).
- Alcohol (interacts with polypharmacy and the liver) and sleep (~7-8 h; the long-sleep arm a marker, not a target) are unchanged (Alcohol and Mortality and Vascular Disease, Sleep Duration and Mortality).
What we cannot yet say — this cut’s main product
The evidence is genuinely thin on the elderly-specific questions, and naming them is much of the value:
- Sarcopenia / anabolic-resistance protein dosing. The mainstream mechanism (anabolic resistance → a higher per-meal leucine threshold → a case for more, pulsed, higher-quality protein; Challenge #22) is plausible but unheld, and sits in tension with the one datum held (the supplement’s lean-mass benefit falls with age). Resolving it needs a dedicated PROT-AGE / per-meal-dose source. Top gap.
- Bone mineral density interventions (loading exercise, protein, weight) — essentially unheld.
- Weight loss with muscle/bone preservation in the elderly — the central trade-off, no elderly-specific trial held.
- Rate of loss and the maintenance phase — unheld (shared with Big Rocks (Median), Challenge #20).
- The obesity paradox in the old — whether mild overweight is protective via physiological reserve — unheld, and it bears on the weight lever.
- Grip strength / muscle mass as predictors — staged (Leong/PURE), not yet ingested (Challenge #17).
- Deprescribing — largely a prescriber act, out of scope — named, not advised on.
- Elderly-specific cardiovascular trials (the SPRINT ≥75 subgroup, HYVET, PROSPER; SCORE2-OP staged).
The honest limits
- This grades the evidence, not the outcome — coherence and source-fidelity, not proof.
- It appraises, it does not prescribe — and that binds harder here: polypharmacy, deprescribing, drug interactions, fall-risk titration and BP/glucose targets in the old are clinician calls.
- A reference class, not a person or everyone: the frail/institutionalised elderly are a different stratum, the fit 70-year-old differs again; the inversions are the default, tuned per case.
- Gap-heavy by construction: the elderly-specific evidence is largely unheld, so much of the “inverts” reasoning is mechanism plus age-moderation, stated as conditionality.